Philip Coxon

Philip Coxon has extensive experience in the pharmaceutical and biotech industry. Philip currently serves as the Vice President of Business Development at Adrestia Therapeutics since September 2022.

Prior to their current role, Philip held various positions at AstraZeneca. Philip was the Senior Director, Transactions, Oncology Business Development & Licensing from July 2021 to September 2022. Before that, they served as the Director, Transactions, Oncology Business Development & Licensing from October 2020 to July 2021. Philip also held the role of Associate Director, Transactions, Oncology Business Development & Licensing from October 2019 to October 2020, and Associate Director, Business Development from January 2018 to October 2019.

Before joining AstraZeneca, Philip worked at Teva Pharmaceuticals where they started as an Associate Director and eventually became the Director, Global Business Development & Strategy. Philip held this role from April 2015 to November 2017. Prior to that, they served as the Alliance Manager, European Business Development from October 2013 to March 2015.

Philip's earlier experience includes working at LifeArc as a Business Development Manager from November 2010 to September 2013. Philip also served as the Therapeutics Review Team Leader from January 2012 to December 2012, and as a Business Manager from April 2008 to October 2010.

Before entering the industry, Philip worked as a Post-Doctoral Scientist at the Institute of Cancer Research from October 2007 to April 2008. Philip also served as a Scientific Officer at the Gray Cancer Institute from October 2006 to August 2007.

Philip's career began with an industrial placement at GSK, where they worked as an Industrial Placement Student from September 2000 to August 2001.

Overall, Philip Coxon has held various roles in business development and strategy within the pharmaceutical and biotech industry, demonstrating their expertise and knowledge in the field.

Philip Coxon completed their academic education with a Bachelor of Science degree in Biochemistry and Physiology (Industry) from the University of Leeds, attending from 1998 to 2002. Afterward, they pursued a Doctor of Philosophy (PhD) degree in Biochemistry and Molecular Biology at The Institute of Cancer Research, from 2003 to 2007.